Rhodia Pharma Solutions and Critical Therapeutics sign long-term supply agreement
Rhodia Pharma Solutions and Critical Therapeutics, both of the US, have signed a long-term supply agreement for the production of the zileuton active pharmaceutical ingredient, which will be manufactured at Rhodia's facility in Annan, Scotland.
Rhodia Pharma Solutions and Critical Therapeutics, both of the US, have signed a long-term supply agreement for the production of the zileuton active pharmaceutical ingredient, which will be manufactured at Rhodia's facility in Annan, Scotland.
Rhodia Pharma Solutions will be responsible for the manufacture of APIs used in the production of various formulations of zileuton, including ZYFLO Filmtab, a tablet formulation of zileuton, which received marketing approval from the US FDA in 1996 for the treatment of asthma in patients 12 years of age and older. Critical Therapeutics owns worldwide marketing and development rights to numerous formulations of zileuton.
The Annan site is a validated cGMP facility for the manufacture of both pharmaceutical intermediates and APIs. Rhodia Pharma Solutions has already produced quantities of Critical Therapeutics' zileuton at both its UK sites in Annan and Dudley. When zileuton manufacturing is consolidated in Annan, it will represent one of the site's major activities.
'We are pleased to welcome Critical Therapeutics as a customer for our GMP facility in Scotland,' said Nick Green, president of Rhodia Pharma Solutions. 'It is evident that the investments we have made in our custom manufacturing operations are paying off.'